Mazen Jizzini
Hematology & Oncology · Tarzana, CANPI 1346702032
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,527 of the $3,962 with a category attached, or 89.0%. It is spread thinly across 29 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 94 payments — averaging $42.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$531
- Sanofi$460
- Gilead$435
- EMD Serono, Inc.$298
- Blueprint Medicines Corporation$271
- Johnson & Johnson$245
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,52789%
- Education$43511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 17 | $531 |
| Sanofi | 14 | $460 |
| Gilead(2 entities) | 6 | $435 |
| EMD Serono, Inc. | 6 | $298 |
| Blueprint Medicines Corporation | 3 | $271 |
| Johnson & Johnson | 5 | $245 |
| Aadi Bioscience, Inc. | 2 | $183 |
| Seagen Inc. | 2 | $171 |
| Secura Bio, Inc. | 1 | $135 |
| Karyopharm Therapeutics Inc. | 1 | $131 |
| AstraZeneca | 7 | $125 |
| Sobi, Inc | 1 | $124 |
| Astellas Pharma US Inc | 2 | $123 |
| Bristol Myers Squibb | 4 | $95 |
| Genentech USA, Inc. | 3 | $87 |
| Incyte Corporation | 2 | $87 |
| Jazz Pharmaceuticals Inc. | 3 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $60 |
| Agios Pharmaceuticals, Inc. | 2 | $47 |
| Regeneron Healthcare Solutions, Inc. | 1 | $39 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Rigel Pharmaceuticals, Inc. | 1 | $31 |
| Progenics Pharmaceuticals, Inc. | 1 | $30 |
| Beone Medicines USA, Inc. | 1 | $28 |
| Amgen | 1 | $26 |
| Geron Corporation | 1 | $24 |
| Merck | 1 | $23 |
| Deciphera Pharmaceuticals Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,962 in reported general payments places this provider in the 50th percentile of 1,363 hematology & oncology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 14 | $203 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Tarzana
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.